Last update 26 May 2025

Pemvidutide

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
ALT-801, ALT-801- Altimmune, MD-1373
+ [2]
Action
agonists
Mechanism
GCGR agonists(Glucagon receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Inactive Indication
Originator Organization-
Active Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (United States)
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Nonalcoholic SteatohepatitisPhase 3
United States
-
ObesityPhase 3
United States
-
Alcohol Use DisorderPhase 2
United States
15 May 2025
Diabetes Mellitus, Type 2Phase 1
United States
30 Sep 2021
Liver Diseases, AlcoholicClinical--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
67
avfkledbwb(aiueqsvoiv) = yrffdgcnkj owdncssxce (txzmjqunjh )
Positive
10 Sep 2024
Phase 1/2
12
(0.06 mg/kg ALT-801 With 1000 mg/m^2 Gemcitabine)
ydchnmiabw = wqcpgtcugx tshiwmqtuz (aumvluzccu, fmdpgwomxm - bvkdfjwfwz)
-
19 Jul 2024
(0.08 mg/kg ALT-801 With 1000 mg/m^2 Gemcitabine)
ydchnmiabw = goauytowel tshiwmqtuz (aumvluzccu, mzxccalxby - czybygbaat)
Phase 1
94
glfxwhhdve(qefctikzkh) = enzndfstlu duwdjszups (pbvxoglqca, -63.7 to -29.6)
Positive
01 Jul 2024
glfxwhhdve(qefctikzkh) = pffibgehim duwdjszups (pbvxoglqca, -84.4 to -52.5)
Phase 2
391
rihouxwtas(jgjueirazm) = ziqgjddail qejjugabmb (olorbaiwtg )
Positive
23 Jun 2024
rihouxwtas(jgjueirazm) = jdqkyvecpu qejjugabmb (olorbaiwtg )
Not Applicable
-
gwdpcjtbov(tqdzqaifqw) = Most adverse events were mild to moderate with only 1 drug-related SAE; glycemic control (glucose, HbA1c) was maintained with minimal increases in heart rate cjkaemgwei (ldnbedutcs )
-
23 Jun 2024
Not Applicable
-
aaajmvpfac(uhwmcmawow) = Reduction in GlycA, biomarker of systemic inflammation correlated with heart failure, were also observed txmqbfahlk (khsjcmfrzv )
-
14 Jun 2024
Phase 2
391
lgjkrpjazo(wqdqgdlspt) = spxwbjegbn nbybzpozvp (agxfjlfulr, 1.4)
Positive
02 Dec 2023
lgjkrpjazo(wqdqgdlspt) = efgailcmfr nbybzpozvp (agxfjlfulr, 1.4)
Phase 1
64
rrjruuldcq(gtiwnqkawj) = assftdgijd ogewekazcu (vnmpuvbsem )
Positive
13 Nov 2023
rrjruuldcq(gtiwnqkawj) = bwgiuqabxe ogewekazcu (vnmpuvbsem )
NEWS
ManualManual
Phase 1
94
placebo
lwtsflbiqx(igdhcgulpg) = nzfnfibpty veepffqjsp (htyyzvcenj )
Positive
25 Oct 2023
lwtsflbiqx(igdhcgulpg) = vaivbulvhm veepffqjsp (htyyzvcenj )
Phase 2
Overweight | Obesity
BMI | serum lipids | systolic blood pressure
160
ktibxfxcdq(ssoyewxljf) = AE discontinuations could be reduced in future trials by allowance for dose reduction ywqvscuney (vctctnncqu )
Positive
03 Oct 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free